Height IS a risk factor for higher-risk prostate cancer

A newly published and very detailed paper based on data from the PRACTICAL consortium now seems to have confirmed that taller men are at greater risk for high-risk prostate cancer than shorter ones (like your sitemaster). … READ MORE …

New test for abiraterone- and enzalutamide-resistant forms of prostate cancer

A group at The Institute for Cancer Research and The Royal Marsden Hospital in the UK — along with other European colleagues — has come up with a new, relatively low-cost test that seems to be able to identify men with advanced forms of prostate cancer who are more or less likely to respond well to treatment with drugs like abirateone acetate and enzalutamide. … READ MORE …

Mutation to inherited HSD3B1 gene associated with more aggressive form of prostate cancer

According to an article to appear in the September issue of The Lancet Oncology, some patients with aggressive prostate cancer are more likely to die earlier from their disease if they carry a specific testosterone-related genetic abnormality. … READ MORE …

Prevalence of DNA-repair germline mutations in men with metastatic prostate cancer

A new study in this week’s New England Journal of Medicine reports that DNA-repair germline mutations were found in nearly 12 percent of patients who had metastatic prostate cancer. … READ MORE …

Can TMPRSS2-ERG gene expression predict low response to taxane therapy?

Drugs like docetaxel and cabazitaxel (taxanes) are among the most active forms of treatment in the management of men with metastatic, castration-resistant prostate cancer (mCRPC), but they don’t work for everyone. … READ MORE …

Is the Decipher test really as useful as it’s manufacturer seems to claim?

A newly published article in the journal PLoS One questions whether the Decipher® test (a 22-gene expression assay test) has actual clinical utility in helping physicians to make good decisions about the follow-up treatment of men with prostate cancer after an initial radical prostatectomy. … READ MORE …

Radiotherapy + “suicide gene” therapy in treatment of localized prostate cancer

A report in the Journal of Radiation Oncology is making big claims for the effectiveness of a combination of intensity-modulated radiation therapy (IMRT) along with “suicide gene” therapy as first-line treatment for localized prostate cancer … but there are some real questions that need real answers. … READ MORE …